Home / Stocks / HQY

Healthequity (HQY, Managed Health Care) Stock Valuation & Fair Value Weak on forward returns

Healthequity (HQY, Managed Health Care) trades at a blended P/E of 20.1, about 62% below its historical normal valuation, with a forward growth estimate of 11.7% and a PEG of 1.72. Analysts' one-year estimates have been hit 36% of the time. Priced at its historical normal P/E of 53.1 on the same blended earnings, the 2026-10-02 close of $90.04 corresponds to about $238 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-10-05
Blended P/E
20.1
Normal P/E
53.1
PEG
1.72
Fwd growth
11.7%
Div yield
0.0%
RSI (14)
50.1
Neutral
Technical context
  • Price $93.05 at the 2026-10-08 close, 1.2% above the 20-day average ($91.95) and 4.7% below the 50-day ($97.64).
  • RSI (14) at 50.1.
  • 52-week range $73.21 to $106.79: the price is 12.9% below the high and 27.1% above the low.

The Street vs SeerForecast

Wall Street's mean price target for HQY is $119.33 across 15 analysts, 28.2% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: weak on forward returns. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been weak on forward returns since 2026-08-21.

Blended P/E and rating by weekBlended P/E moved from 23.7 to 20.1 between 2026-08-21 and 2026-10-02, against a normal P/E of 53.1, with 0 rating changes over 16 recorded weeks.2026-08-21: P/E 23.7, Weak on forward returns, recalculated for the week of 2026-08-212026-08-21: P/E 24.0, Weak on forward returns, recorded live 2026-08-242026-08-27: P/E 24.0, Weak on forward returns, recalculated for the week of 2026-08-272026-08-28: P/E 24.0, Weak on forward returns, recalculated for the week of 2026-08-282026-08-28: P/E 24.0, Weak on forward returns, recalculated for the week of 2026-08-302026-08-28: P/E 21.8, Weak on forward returns, recorded live 2026-08-312026-09-04: P/E 21.8, Weak on forward returns, recalculated for the week of 2026-09-052026-09-04: P/E 21.7, Weak on forward returns, recorded live 2026-09-072026-09-11: P/E 21.7, Weak on forward returns, recalculated for the week of 2026-09-122026-09-11: P/E 21.7, Weak on forward returns, recorded live 2026-09-142026-09-18: P/E 21.7, Weak on forward returns, recalculated for the week of 2026-09-192026-09-18: P/E 21.4, Weak on forward returns, recorded live 2026-09-212026-09-25: P/E 21.4, Weak on forward returns, recalculated for the week of 2026-09-262026-09-25: P/E 19.8, Weak on forward returns, recorded live 2026-09-282026-10-02: P/E 19.8, Weak on forward returns, recalculated for the week of 2026-10-032026-10-02: P/E 20.1, Weak on forward returns, recorded live 2026-10-0520.030.040.050.0Aug 21Aug 31Sep 11Sep 22Oct 2Normal P/E 53.1
Weak on forward returns

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-08-21P/E 23.7-55%Weak on forward returns (recalculated)
2026-08-24P/E 24.0-55%Weak on forward returns
2026-09-28P/E 19.8-63%Weak on forward returns
2026-10-05P/E 20.1-62%Weak on forward returns ← now
Show all 16 weeks
WeekBlended P/EPremium to normal P/ERating
2026-08-21P/E 23.7-55%Weak on forward returns (recalculated)
2026-08-24P/E 24.0-55%Weak on forward returns
2026-08-27P/E 24.0-55%Weak on forward returns (recalculated)
2026-08-28P/E 24.0-55%Weak on forward returns (recalculated)
2026-08-30P/E 24.0-55%Weak on forward returns (recalculated)
2026-08-31P/E 21.8-59%Weak on forward returns
2026-09-05P/E 21.8-59%Weak on forward returns (recalculated)
2026-09-07P/E 21.7-59%Weak on forward returns
2026-09-12P/E 21.7-59%Weak on forward returns (recalculated)
2026-09-14P/E 21.7-59%Weak on forward returns
2026-09-19P/E 21.7-59%Weak on forward returns (recalculated)
2026-09-21P/E 21.4-60%Weak on forward returns
2026-09-26P/E 21.4-60%Weak on forward returns (recalculated)
2026-09-28P/E 19.8-63%Weak on forward returns
2026-10-03P/E 19.8-63%Weak on forward returns (recalculated)
2026-10-05P/E 20.1-62%Weak on forward returns ← now

Frequently asked questions

Is Healthequity stock overvalued?

At a blended P/E of 20.1 versus its historical normal P/E of 53.1, Healthequity trades about 62% below its typical valuation, with a PEG of 1.72 on 11.7% forward growth. tickerseer currently rates it weak on forward returns.

What is Healthequity's fair value and PEG?

Healthequity trades at a blended P/E of 20.1 against a historical normal P/E of 53.1, a PEG of 1.72, and a forward growth estimate of 11.7%. Priced at its historical normal P/E of 53.1 on the same blended earnings, the 2026-10-02 close of $90.04 corresponds to about $238 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Healthequity changed?

tickerseer's rating has been weak on forward returns since 2026-08-21.

What is the analyst price target for Healthequity?

The mean Wall Street price target for Healthequity is $119.33 across 15 analysts, 28.2% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Managed Health Care. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track HQY free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.